InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: None

Saturday, 01/16/2021 8:29:39 PM

Saturday, January 16, 2021 8:29:39 PM

Post# of 403325
Noticed this on the “corporate overview”. Most have probably seen it but it is a good reminder of secondary prospects.

Page 24.

• Anchor Each Drug Candidate in Additional Trials to Further Provide Favorable Return-On-Investment
• Clinical trial plans advancing with Brilacidin for COVID-19 (IV administration) and for Ulcerative Colitis (delayed release oral formulation)

https://static1.squarespace.com/static/5715352e20c647639137f992/t/5efa0ab609029f1bcea6f226/1593445056215/IPIX+Corporate+Overview+June+2020+.pdf



Go Leo & IPIX!

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating
COVID-19

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News